Oil prices turn lower as Bessent says U.S. may have Iran deal "today or tomorrow"
Introduction & Market Context
Exagen Inc. (NASDAQ:XGN) presented its second-quarter 2026 results on August 4, highlighting record revenue and significant progress toward profitability in the autoimmune diagnostics market. The company’s shares surged 35.9% to $6.36 following the presentation, as investors responded to both the strong quarterly performance and raised full-year guidance.
The Vista, California-based company, which specializes in precision diagnostics for autoimmune diseases, reported revenue of $19.9 million for the quarter ended June 30, 2026, representing 16% year-over-year growth and beating analyst expectations by nearly 12%. More significantly, the company’s adjusted EBITDA loss narrowed to just $100,000 from $1.7 million in the prior-year period, bringing the company within striking distance of breakeven.
Quarterly Performance Highlights
The presentation detailed several record-breaking metrics for the second quarter. AVISE CTD test volume reached nearly 39,000, an 11% increase from the prior year, while AVISE CTD revenue totaled $17.7 million. The company’s trailing 12-month average selling price (ASP) climbed to $446 per test, marking the 13th consecutive quarter of growth and representing a 4% year-over-year increase.
As shown in the following summary of Q2 2026 financial results, the company demonstrated improvement across all key performance indicators:
Gross margin expanded to 61.2%, up approximately 90 basis points from the prior year, driven by higher pricing, volume growth, and improved laboratory efficiency. Operating expenses rose just 7% year-over-year to $13.9 million, demonstrating disciplined cost management even as revenue accelerated.
The company also generated $3.1 million in cash during the quarter and ended with total liquidity of $77 million, including cash, accounts receivable, and available credit facilities, as illustrated in the balance sheet highlights:
Clinical Differentiation & Market Opportunity
Exagen’s presentation emphasized the significant unmet need in autoimmune disease diagnosis, noting that more than 41 million Americans test positive for antinuclear antibodies (ANA), the first-line screen for autoimmune disease. Among this population, approximately 1 million have been diagnosed with lupus and 2 million with rheumatoid arthritis.
The diagnostic challenge is substantial. As detailed in the presentation, lupus diagnosis can take up to six years, involving 15 doctor visits and 58 lab procedures, while rheumatoid arthritis diagnosis can take two years and consultations with four different physicians:
The clinical imperative for faster diagnosis is clear. Earlier intervention in lupus leads to a 25% reduction in disease-related hospitalization and a 1.5-fold reduction in mortality risk related to irreversible organ damage. For rheumatoid arthritis, inflammation can lead to articular damage and bone erosion within the first two years without treatment:
Exagen’s AVISE testing platform addresses these challenges through proprietary biomarkers and algorithmic interpretation. The company’s data shows that AVISE CTD achieves 80% sensitivity for lupus diagnosis, significantly outperforming conventional biomarkers such as anti-Smith (14%), anti-dsDNA (33%), and complement C3/C4 (44%):
The company has completed more than 1.2 million AVISE CTD tests and built a substantial evidence base, including 15 peer-reviewed publications and analysis of approximately 50,000 patients in the CAPSTONE study. This real-world evidence demonstrates that AVISE-positive patients are 5.1 times more likely to receive a systemic lupus erythematosus diagnosis and 2.8 times more likely to start therapy, while AVISE-negative patients show an average annual lab-cost reduction of $985:
The presentation positioned Exagen’s opportunity within a growing autoimmune diagnostics market estimated at more than $2 billion, where the company currently holds approximately 3% market share. Management projects the market will grow at a 5% compound annual growth rate through 2033:
Strategic Progress & Product Innovation
The company’s improved performance reflects several years of strategic repositioning. Following a period of volume decline in 2024, when management deliberately emphasized ASP expansion over volume growth, the business has returned to growth across both dimensions.
Volume trends have resumed their upward trajectory, as shown in the following chart:
Simultaneously, both revenue and average selling price have expanded consistently. Revenue has grown from approximately $45 million in 2022 to $65 million in 2025, while trailing 12-month ASP increased from $420 to $455 over the same period:
Product innovation has contributed to ASP growth. In 2025, Exagen launched two significant enhancements to its AVISE CTD platform: the addition of T-cell markers for lupus, which improves sensitivity and carries patent protection through 2035, and the incorporation of anti-RA33 and anti-PAD4 markers for rheumatoid arthritis, which enable detection of 30% of seronegative RA patients:
The company’s innovation pipeline extends beyond these enhancements. Exagen is prioritizing development of a myositis test, targeting a disease with more than 100,000 U.S. patients that frequently suffers from misdiagnosis. The company noted that 80% of clinicians lack confidence in standard testing results for this condition:
The broader pipeline includes projects addressing lupus nephritis, SLE disease activity, and RA disease activity, with clear prioritization based on clinical and commercial impact:
Financial Trajectory & Path to Profitability
The presentation detailed the financial transformation underway at Exagen. Comparing 2022-2024 averages to 2025 performance, the company has accelerated revenue growth from 5% to 20%, turned volume growth from negative 1% to positive 11%, expanded gross margin from 54% to 58%, and improved adjusted EBITDA margin from negative 46% to negative 15%:
Management provided specific guidance on the path to sustained profitability. The company expects to reach adjusted EBITDA breakeven at approximately $80 million in annual revenue with gross margins of approximately 63%. The presentation included a detailed breakeven analysis showing the convergence of revenue and total costs at this threshold:
With second-quarter annualized revenue of approximately $80 million and gross margins already exceeding 61%, the company appears positioned to achieve this milestone in the near term, particularly given the raised full-year guidance.
Forward-Looking Statements
Exagen raised its full-year 2026 revenue outlook to a range of $72 million to $75 million, up from prior guidance of $70 million to $73 million. The increased guidance reflects stronger first-half execution and confidence in continued momentum:
The updated outlook incorporates high-single-digit volume growth and mid-single-digit ASP growth compared to the fourth-quarter 2025 exit rate. Management expects gross margins to remain at or above 60% for the full year.
Beyond 2026, the company is preparing for the early 2027 commercialization of its myositis product, with plans to train its 45-territory sales force on the new offering in the third quarter of 2026. The company also continues to build its Pharma Services business, which generated more than $1 million in revenue during the second quarter, up more than 200% year-over-year, with a backlog exceeding $6 million.
The presentation emphasized three strategic priorities: advancing adoption through sales force expansion and clinical evidence, expanding ASP through improved revenue cycle management and payer engagement, and driving innovation through new product development and potential acquisitions:
With 16 issued patents and 5 pending, including protection extending through 2045 for certain technologies, Exagen has built substantial intellectual property barriers around its platform. The company’s extensive clinical validation, demonstrated through peer-reviewed publications analyzing thousands of patients, provides additional competitive differentiation in discussions with payers and healthcare systems:
The strong second-quarter results and raised guidance suggest that Exagen’s multi-year strategic repositioning is gaining traction. As the company approaches profitability with a clear path to breakeven, expanding product portfolio, and growing body of clinical evidence, it appears well-positioned to capture a larger share of the substantial autoimmune diagnostics market while delivering improved returns to shareholders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Is now the time to buy XGN?
ProPicks AI evaluates XGN every month against thousands of alternatives using 100+ financial metrics.
It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could XGN be next—or is there a better opportunity in the same space?
Don't wait to find out.